García-Luna A, Nez-Esquivel VH, López-Baca F, Mora-Constantino J

Language: Spanish
References: 11
Page: 47-51
PDF size: 245.94 Kb.

ABSTRACT

Background: Granulomatosis with polyangiitis (Wegener’s granulomatosis) is a rare, multisystem and autoimmune disease of unknown etiology. Its primary features include pauci-immune necrotizing granulomatous inflammation of small and medium vessel vasculitis; its prevalence is 1-9/100,000 and the typical age of onset is between 35 and 55 years. As a multisystem disease, it can affect any area of the body, with predilection for the lungs and kidneys. Case report: 57-year-old female with one month of evolution characterized by clinical evidence of respiratory and renal failures requiring intubation and hemodialysis; she had a poor outcome upon her admission to the ICU, with positive c-ANCA. She was treated with rituximab, high doses of glucocorticoids and plasma exchange, achieving the recovery of her kidney and lung functions. Conclusions: Manifestations of granulomatosis with polyangiitis may occur in a fulminant way; 50% of chest imaging studies show cavitated nodules, which, coupled with crescentic necrotizing glomerulonephritis and the presence of c-ANCA (sensitivity of 96-98%), support the diagnosis, which is confirmed by biopsy. Current treatment with rituximab, corticosteroids and plasma exchange to induce remission increases five-year survival in 75% of the patients.

REFERENCES

1. Falk RJ, Gross WL, Guillevin L, Hoffman GS, Jayne DR, Jennette JC. Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Arthritis Rheum. 2011; 63 (4): 863-864.

2. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992; 116 (6): 488-498.

3. Kallenberg CG. Pathophysiology of ANCA-associated small vessel vasculitis. Curr Rheumatol Rep. 2010; 12: 399-405.

4. Manganelli P, Fietta P, Carotti M, Pesci A, Salaffi F. Respiratory system involvement in systemic vasculitis. Clin Exp Rheumatol. 2006; 24: S48-S59.

5. Holle JU, Gross WL. Neurological involvement in Wegener’s granulomatosis. Curr Opin Rheumatol. 2011; 23: 7-11.

6. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008; 67: 1004-1010.

7. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013; 369 (5): 417-427.

8. Garcia-Valladares I, Espinoza LR. Is rituximab superior to cyclophosphamide for ANCA-associated vasculitis for induction of remission, and with a better safety profile? Curr Rheumatol Rep. 2010; 12: 395-398.

9. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007; 18: 2180-2188.

10. Ntatsaki E, Carruthers D, Chakravarty K, D’Cruz D, Harper L, Jayne D et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014; 53 (12): 2306-2309.

11. Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. 2008; 26: S94-S104.